Tagged with Peptides

Pharma Faces: Zealand’s Emmanuel Dulac Targeting 5 Commercialised Products by 2025
Peptides: Technological Maturity Leading to Big Investments & Breakthroughs
Emmanuel Dulac – President & CEO, Zealand Pharma
Carlo Toniatti – CSO, IRBM
IRBM CSO Carlo Toniatti on the Evolving CRO Role in Drug Development, Emerging Approaches in Oncology & the Potential of AI
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here